Summarized Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 10,986	$ 6,570	$ 2,088	$ 9,206	$ 6,081	$ 9,120	$ 7,367	$ 4,614	$ 28,850	$ 27,182	$ 28,947
Gross profit	5,069	179	27	1,402	1,231	1,340	1,564	691
Loss from continuing operations	(23,602)	(16,618)	(18,246)	(10,220)	(11,862)	(12,981)	(6,696)	(10,165)	(69,634)	(57,605)	61,571
Loss (income) from discontinued operations	109	(379)	(582)	(169)	3,019	(1,635)	79,160	(12,696)	(1,021)	67,848	(52,900)
Net (loss) income	$ (23,493)	$ (16,997)	$ (18,828)	$ (10,389)	$ (8,843)	$ (14,616)	$ 72,464	$ (22,861)	$ (69,707)	$ 26,144	$ 8,587
Net income (loss) per share, basic and diluted (in dollars per share)	$ (0.95)	$ (0.69)	$ (0.76)	$ (0.42)	$ (0.36)	$ (0.65)	$ 3.78	$ (1.19)
Net income (loss) per share, diluted (in dollars per share)									$ (2.81)	$ 1.22	$ 0.48
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of business									$ 0	$ 0	$ 79,980
Loss on extinguishment of debt									0	0	1,254
Zohydro ER [Member]
Quarterly Financial Information Disclosure [Abstract]
Loss (income) from discontinued operations									(1,021)	67,848	(52,900)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of business					$ 2,323	$ 2,474	$ 75,575
Tax benefit (expense)					3,472	5,496	$ 6,946		$ (88)	$ (14,060)	0
Recognition of contingent consideration					$ 385
Impairment of long-lived assets						$ (5,485)
Sumavel DosePro [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of long-lived assets	$ (8,431)										$ (838)